A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy-Reference-Cited by-同舟云学术

A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy

Published:2017-08-11 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Fujihara Clarice K.,Kowala M. C.,Breyer M. D.,Sena Claudia R.,Rodrigues Mariliza V.,Arias Simone C. A.,Fanelli Camilla,Malheiros Denise M.,Jadhav P. K.,Montrose-Rafizadeh Chahrzad,Krieger Jose E.^ORCID,Zatz Roberto

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-017-08383-2.pdf

Reference36 articles.

1. Brown, N. J. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat. Rev. Nephrol. 9, 459–469 (2013).

2. Bianchi, S., Batini, V. & Bigazzi, R. The renal effects of mineralocorticoid receptor antagonists. Int. J. Cardiol. 200, 20–24 (2015).

3. Aldigier, J. C., Kanjanbuch, T., Ma, L. J., Brown, N. J. & Fogo, A. B. Regression of existing glomerulosclerosis by inhibition of aldosterone. J. Am. Soc. Nephrol. 16, 3306–3314 (2005).

4. Chen, H. et al. Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress. Kidney Blood Press Res. 37, 557–566 (2013).

5. Ikeda, H. et al. Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats. Kidney Int 75, 147–155 (2009).

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cafeteria Diet-Induced Obesity Worsens Experimental CKD;Nutrients;2023-07-26

2. Implications of Senescent Cell Burden and NRF2 Pathway in Uremic Calcification: A Translational Study;Cells;2023-02-17

3. Nephrons, podocytes and chronic kidney disease: Strategic antihypertensive therapy for renoprotection;Hypertension Research;2022-10-12

4. The mineralocorticoid receptor in chronic kidney disease;British Journal of Pharmacology;2021-12-28

5. Role of mineralocorticoid receptor antagonists in kidney diseases;Drug Development Research;2020-11-12